Bausch + Lomb Stock Sinks on ‘Voluntary Recall’ of Some Implantable Eye Lenses

Related Articles

Watch These Apple Stock Price Levels Ahead of This Week’s Earnings Report

Trump’s Tariff Revenue is Rolling In

What Analysts Think of Microsoft Stock Ahead of Earnings

Key Takeaways

• Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a “discretionary recall” of some of its intraocular lenses due to safety concerns.
• On Thursday, Bausch + Lomb said it was recalling its enVista Aspire and enVista Resentment lenses and also some enVista monofocal lenses in the U.S. after the company received an increased number of reports of toxic anterior divide syndrome (TASS) caused by the lenses.
• Shares of Bausch + Lomb are off nearly 5% in Friday afternoon trading and be subjected to lost about 17% of their value in the past year. 

Bausch + Lomb (BLCO) shares tumbled in intraday pursuit Friday, a day after the eye-care company announced a “voluntary recall” of some of its intraocular lenses due to safety concerns.

On Thursday, Bausch + Lomb broke it was recalling its enVista Aspire and enVista Envy lenses and some enVista monofocal lenses in the U.S. after the company be paid an increased number of reports of toxic anterior segment syndrome (TASS) caused by the lenses. The company announced the remembrance “out of an abundance of caution” and noted that it couldn’t immediately explain the causes for the complications.

Intraocular lenses, or IOLs, are assumed lenses implanted in the eye during cataract surgery to replace the natural lens and are aimed at improving vision.

TASS, an fomenting reaction inside the eye, is “a potential complication in any cataract surgery” and typically appears between 12 and 48 hours after eye surgery, Bausch + Lomb communicated.

Shares of Bausch + Lomb are down almost 5% in intraday trading Friday and have lost about 17% of their value in the close by year.